AERI - Aerie Pharmaceuticals, Inc.
| Previous Close | 54.75 |
| Open | 55.00 |
| Bid | 43.65 x 100 |
| Ask | 0.00 x 0 |
| Day's Range | 53.75 - 55.60 |
| 52 Week Range | 38.14 - 66.60 |
| Volume | 149,861 |
| Avg. Volume | 326,091 |
| Market Cap | 2.131B |
| Beta | 0.48 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.11 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 83.30 |
Markit•9 days agoSee what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
Short interest is moderately high for AERI with between 10 and 15% of shares outstanding currently on loan. Over the last one-month, outflows of investor capital in ETFs holding AERI totaled $10 million.
- Business Wire•13 days ago
Aerie Pharmaceuticals Announces Appointment of Scott Laranjo as Director, Marketing, Roclatan™
Aerie Pharmaceuticals, Inc. , an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Scott Laranjo as Director, Marketing, RoclatanTM, reporting to Deanne Melloy, Aerie’s Vice President of Marketing.
- Zacks•23 days ago
Aerie Pharmaceuticals (AERI) Up 4.6% Since Earnings Report: Can It Continue?
Aerie Pharmaceuticals (AERI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- InvestorPlace•29 days ago
3 Sell-Rated Drug Stocks Investors Should Avoid for Now
The overall investor sentiment toward pharma and biotech stocks has improved of late as investors are focusing more on fundamentals than on issues like drug pricing. The year 2017 saw a number of drugs like Rhopressa, Tymlos, Ozempic, Vyzulta, Siliq, Trulance, Hemlibra, among others getting approval. Lutathera, Ilumya, Symdeko, Biktarvy, Erleada have already been approved in 2018 and investors are expected to keep their focus on the same. While 2017 was pretty ho-hum on this front with just a few key deals, 2018 is expected to see a surge in M&A primarily due to lower U.S. tax rates. Taking a clue from Gilead Sciences GILD acquisition of Kite Pharma, Celgene CELG recently acquired Juno Therapeutics to gain traction in the promising CAR-T space. Sanofi SNY acquired Bioverativ Inc. which focuses on therapies for hemophilia and other rare blood disorders.
- Zacks•29 days ago
3 Sell-Rated Drug Stocks Investors Should Avoid for Now
Despite a fairly upbeat performance of the pharma and biotech sector, caution has to be exercised before choosing a stock for investment as a few drug companies are struggling to revive business.
- GlobeNewswire•last month
Investor Expectations to Drive Momentum within JELD-WEN Holding, Nathan's Famous, Aerie Pharmaceuticals, RBC Bearings, Malibu Boats, and United Therapeutics — Discovering Underlying Factors of Influence
NEW YORK, March 21, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- Business Wire•last month
Aerie Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference
Aerie Pharmaceuticals, Inc. , an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside chat discussion at the 17th Annual Needham Healthcare ...
- Simply Wall St.•last month
Is There Now An Opportunity In Aerie Pharmaceuticals Inc (NASDAQ:AERI)?
Aerie Pharmaceuticals Inc (NASDAQ:AERI), a pharmaceuticals company based in United States, saw a decent share price growth in the teens level on the NasdaqGM over the last few months. AsRead More...
- Business Wire•last month
Aerie Pharmaceuticals to Present at the Oppenheimer & Co. 28th Annual Healthcare Conference
Aerie Pharmaceuticals, Inc. , an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced that Richard Rubino, Chief Financial Officer, will present in a fireside chat discussion at the Oppenheimer & Co.
- American City Business Journals•2 months ago
Aerie changes HQ to Durham, giving the Triangle another public company
Aerie's facility in Durham is the company's largest in the U.S., with more than 45,000 square feet, upward of 50 employees, and a unique mix of laboratory and office space – at a ratio of about 60 percent to 40 percent. For Aerie, "regardless of size, Durham remains an important center of gravity for the company, with our heritage in the work of Dr. David Epstein at Duke, the drug discovery and pre-clinical science that led to our breakthrough first product in glaucoma and our large kinase library, and the ongoing development work that is filling our product pipeline," says Heitmann.
- Business Wire•2 months ago
Aerie Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference
Aerie Pharmaceuticals, Inc. , an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside chat discussion at the Cowen and Company 38th Annual ...
Markit•2 months agoSee what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
Short interest is moderately high for AERI with between 10 and 15% of shares outstanding currently on loan. The $201 million in inflows that ETFs holding AERI received over the last one-month is a decline from earlier in the period and among the weakest of the past year.
- ACCESSWIRE•2 months ago
Blog Exposure - Merck to Present Data from Studies of Investigational HIV Therapies Doravirine and MK-8591 at Conference on Retroviruses and Opportunistic Infections 2018
Stock Monitor: Aerie Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 05, 2018 / Active-Investors.com has just released a free research report on Merck & Co., Inc. (NYSE: MRK ). If you want ...
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of AERI earnings conference call or presentation 28-Feb-18 10:00pm GMT
Q4 2017 Aerie Pharmaceuticals Inc Earnings Call
- Zacks•2 months ago
Aerie's (AERI) Q4 Loss Wider on Higher Operating Expenses
Aerie (AERI) incurs a wider-than-expected loss in the fourth quarter due to higher operating expenses.
- Associated Press•2 months ago
Aerie reports 4Q loss
The Irvine, California-based company said it had a loss of $1.60 per share. Losses, adjusted for non-recurring costs, were $1.38 per share. The results missed Wall Street expectations. The average estimate ...
- Business Wire•2 months ago
Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update and 2018 Guidance
Aerie Pharmaceuticals, Inc. , an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2017, along with a general business update and 2018 guidance.
- ACCESSWIRE•2 months ago
Aerie Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 28, 2018 / Aerie Pharmaceuticals, Inc. (NASDAQ: AERI ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 28, 2018, at 5:00 ...
- Zacks•2 months ago
Why Earnings Season Could Be Great for Aerie Pharmaceuticals (AERI)
Aerie Pharmaceuticals (AERI) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.
- Zacks•2 months ago
Can Rhopressa's Approval Drive Aerie (AERI) in Q4 Earnings?
Aerie (AERI) looks poised for a beat when it reports Q4 results (due on Feb 28) on the back of lead drug Rhopressa's approval.
Markit•2 months agoSee what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
Short interest is moderately high for AERI with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on February 6. Over the last one-month, outflows of investor capital in ETFs holding AERI totaled $396 million.
- Business Wire•2 months ago
Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Wednesday, February 28, 2018
Aerie Pharmaceuticals, Inc. , announced today that its fourth quarter and full year 2017 financial results will be released after the market closes on Wednesday, February 28, 2018.
- Business Wire•2 months ago
Aerie Pharmaceuticals Announces Appointment of John LaRocca as General Counsel
Aerie Pharmaceuticals, Inc. , an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of John LaRocca as General Counsel, reporting to Vicente Anido, Jr., Ph.D., Aerie’s Chairman and Chief Executive Officer.
- Business Wire•2 months ago
Aerie Pharmaceuticals Announces Appointment of Scott Cassady as Regional Sales Director for the Central Region
Aerie Pharmaceuticals, Inc. , an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Scott Cassady as Regional Sales Director for the Central Region, reporting to Gary Menichini, Aerie’s Vice President of Sales....
Markit•2 months agoSee what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
Aerie Pharmaceuticals Inc NASDAQ NMS:AERI
